Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s692, 2025. DOI: 10.25251/w6str133. Disponível em: https://skin.dermsquared.com/skin/article/view/3778. Acesso em: 30 apr. 2026.